Firebrick Pharma (ASX:FRE) - Key People
ASX:FRE · Directors, executives and key personnel · 12 month lookback
Mentioned in
Firebrick wins Philippine OTC approval for Nasodine with Q1 2027 launch possible
16 Oct 2026
Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026
26 Sept 2026
Firebrick receives $293,000 R&D payment as Nasodine pipeline expands
23 Sept 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Also Mentioned
People named in Firebrick Pharma (ASX:FRE) articles over the last 12 months, by frequency.
K Watson
· 7 articles
Al Moghadd
· 6 articles
Matthew Wright
· 5 articles
Rick Legleiter
· 5 articles
Stephen Goodall
· 4 articles
Nilesh Wadhwa
· 4 articles
Al Moghadd - US Commercial Director and Executive Director of Firebrick Pharma, Inc.
· 2 articles
Peter Molloy - Executive Chairman
· 2 articles
Stephen Goodall - Director of Firebrick Pharma, Inc.
· 2 articles
Nilesh Wadhwa - Head of Business Development
· 2 articles
Simon Tucker
· 2 articles
Monique Baldwin
· 2 articles
Stephen Buckley
· 2 articles
Chris Watts
· 2 articles
Rishi Nandiraju
· 2 articles
Albert-Jan Santillana - President and CEO of the S. V. More Group of Companies
· 1 article
Peter Molloy - CEO and Executive Chairman of Firebrick Pharma
· 1 article
Heidi Cuthbert
· 1 article
Phyllis Gardner
· 1 article